Evidence map›Paper›PMID 22532802›Full record

Trial reportPLoS pathogens2012

Induction of strain-transcending antibodies against Group A PfEMP1 surface antigens from virulent malaria parasites.

Ashfaq Ghumra, Jean-Philippe Semblat, Ricardo Ataide, Carolyne Kifude, Yvonne Adams, Antoine Claessens, Damian N Anong, Peter C Bull, Clare Fennell, Monica Arman and 7 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. ExploringFrontiers in immunology · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 5 countries.

Ashfaq GhumraCentre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Jean-Philippe Semblat
Ricardo Ataide
Carolyne Kifude
Yvonne Adams
Antoine Claessens
Damian N Anong
Peter C Bull
Clare Fennell
Monica Arman
Alfred Amambua-Ngwa
Michael Walther
David J Conway
Lalla Kassambara
Ogobara K Doumbo
Ahmed Raza
J Alexandra Rowe
University of Edinburgh · GBCentre for Immunity, Infection and Evolution · GBMRC Unit the Gambia · GMUniversity of Bamako · MLKenya Medical Research Institute · KEUniversity of Buea · CM

Funding

Medical Research Council MC_U190081987Wellcome Trust 084226Wellcome Trust 084535Wellcome Trust 095831
6 · The paper itself

Abstract

Sequence diversity in pathogen antigens is an obstacle to the development of interventions against many infectious diseases. In malaria caused by Plasmodium falciparum, the PfEMP1 family of variant surface antigens encoded by var genes are adhesion molecules that play a pivotal role in malaria pathogenesis and clinical disease. PfEMP1 is a major target of protective immunity, however, development of drugs or vaccines based on PfEMP1 is problematic due to extensive sequence diversity within the PfEMP1 family. Here we identified the PfEMP1 variants transcribed by P. falciparum strains selected for a virulence-associated adhesion phenotype (IgM-positive rosetting). The parasites transcribed a subset of Group A PfEMP1 variants characterised by an unusual PfEMP1 architecture and a distinct N-terminal domain (either DBLα1.5 or DBLα1.8 type). Antibodies raised in rabbits against the N-terminal domains showed functional activity (surface reactivity with live infected erythrocytes (IEs), rosette inhibition and induction of phagocytosis of IEs) down to low concentrations (<10 µg/ml of total IgG) against homologous parasites. Furthermore, the antibodies showed broad cross-reactivity against heterologous parasite strains with the same rosetting phenotype, including clinical isolates from four sub-Saharan African countries that showed surface reactivity with either DBLα1.5 antibodies (variant HB3var6) or DBLα1.8 antibodies (variant TM284var1). These data show that parasites with a virulence-associated adhesion phenotype share IE surface epitopes that can be targeted by strain-transcending antibodies to PfEMP1. The existence of shared surface epitopes amongst functionally similar disease-associated P. falciparum parasite isolates suggests that development of therapeutic interventions to prevent severe malaria is a realistic goal.

Indexed as

Africa South of the SaharaAnimalsAntibodies, ProtozoanAntigens, ProtozoanErythrocytesFemaleHumansMalaria, FalciparumMalePlasmodium falciparumProtein Structure, TertiaryProtozoan ProteinsRabbitsAntibodies, ProtozoanAntigens, Protozoanerythrocyte membrane protein 1, Plasmodium falciparumProtozoan Proteins

Identifiers

PMID22532802
PMCPMC3330128
OpenAlexW2076443493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.